Halozyme Therapeutics, Inc. vs. Immunovant, Inc. Common Stock
Halozyme Therapeutics, Inc. and Immunovant, Inc. Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| HALO | IMVT | |
|---|---|---|
| Market Cap | $12.45 billion | $7.72 billion |
| Revenue (TTM) | $1.66 billion | — |
| Net Income (TTM) | $413.60 million | — |
HALO leads on 1 of 1 size & scale factors.
Valuation
| HALO | IMVT | |
|---|---|---|
| P/E Ratio | 32.63 | — |
| Price / Book | 86.72 | — |
| Price / Sales | 7.48 | — |
HALO and IMVT split the valuation factors evenly.
Profitability
| HALO | IMVT | |
|---|---|---|
| Net Margin | 24.86% | — |
| Return on Equity | 288.13% | — |
HALO and IMVT split the profitability factors evenly.
Risk & Sentiment
| HALO | IMVT | |
|---|---|---|
| Short Interest | 9.79% | 0.15% |
IMVT leads on 1 of 1 risk & sentiment factors.
Dig deeper: HALO overview, HALO financials, IMVT overview, IMVT financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.